



(11) **EP 1 853 915 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
12.10.2011 Bulletin 2011/41

(51) Int Cl.:
G01N 33/53 (2006.01) G01N 33/566 (2006.01)
C07K 17/00 (2006.01) B01L 3/00 (2006.01)

(21) Application number: **06720716.7**

(86) International application number:
PCT/US2006/005095

(22) Date of filing: **14.02.2006**

(87) International publication number:
WO 2006/088823 (24.08.2006 Gazette 2006/34)

(54) **METHOD FOR DETECTING MISFOLDED PROTEINS AND PRIONS**

VERFAHREN ZUM NACHWEIS FALSCH GEFALTETER PROTEINE UND PRIONEN

PROCEDE DE DETECTION DE PROTEINES ET DE PRIONS A REPLIEMENT INCORRECT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(56) References cited:
WO-A-02/097444 WO-A-2005/057166
WO-A-2006/031644 WO-A2-01/77687
WO-A2-02/053723 CA-A1- 2 443 929
US-A- 4 444 879 US-A- 6 166 187

(30) Priority: **15.02.2005 US 652733 P**

(43) Date of publication of application:
14.11.2007 Bulletin 2007/46

(73) Proprietor: **Adlyfe, Inc.**
Rockville MD 20850 (US)

(72) Inventors:
• **ORSER, Cindy, S.**
Lafayette, CO 80026 (US)
• **PAN, Tao**
Gaitherburg, MD 20878 (US)
• **SETHI, Jasmeet**
Germantown, MD 20874 (US)

(74) Representative: **Pohlman, Sandra M.**
df-mp
Fünf Höfe
Theatinerstrasse 16
80333 München (DE)

- **GROSSET ET AL: "Rapid presymptomatic detection of PrP<Sc> via conformationally responsive palindromic PrP peptides" PEPTIDES, ELSEVIER, AMSTERDAM, vol. 26, no. 11, 1 November 2005 (2005-11-01), pages 2193-2200, XP005137424 ISSN: 0196-9781**
- **TCHERKASSKAYA OLGA ET AL: "Conformational biosensor for diagnosis of prion diseases" BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 27, no. 9, 1 May 2005 (2005-05-01), pages 671-675, XP002468292 ISSN: 0141-5492**
- **TCHERKASSKAYA O ET AL: "THE ROLE OF HYDROPHOBIC INTERACTIONS IN AMYLOIDOGENESIS: EXAMPLE OF PRION-RELATED POLYPEPTIDES" JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, ADENINE PRESS, NEW YORK, NY, US, vol. 21, 1 December 2003 (2003-12-01), pages 353-365, XP008078480 ISSN: 0739-1102**
- **NICOTERA P.: 'A route for Prion Neuroinvasion' NEURON vol. 31, 16 August 2001, pages 345 - 348, XP003009927**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 853 915 B1

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application relies on, and claims the benefit of the filing date of, U.S. provisional patent application number 60/652,733, filed 15 February 2005.

BACKGROUND OF THE INVENTION

[0002] The invention relates to the field of detection of proteins in biological samples. More specifically, the invention relates to methods and kits for detecting proteins and prions in a sample containing biological substances, and compositions employed by those methods and kits.

[0003] Numerous diseases and disorders affecting humans and animals have been determined or postulated to involve misfolded cellular proteins. Misfolding of naturally occurring normal cellular proteins is thought to cause the protein to lose activity, or, in many cases, behave abnormally. Misfolding of normal cellular proteins often causes formation of high molecular weight deposits or plaques within affected cells. Diseases that are known or thought to be associated with such misfolding of normal cellular proteins include Alzheimer's disease (AD), in which the A beta (amyloid beta) protein is involved; cerebral amyloid angiopathy (CAA); Parkinson's Disease, in which α -synuclein deposits in Lewy bodies are involved; Pick's Disease and frontal temporal dementia, in which the tau protein is involved; Amyotrophic Lateral Sclerosis (ALS), in which superoxide dismutase is involved; Huntington's Disease, in which the protein huntingtin is involved; and the numerous Transmissible Spongiform Encephalopathies (TSE), such as Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), Bovine Spongiform Encephalopathy (BSE; Mad Cow Disease), in which prion proteins are involved.

[0004] Many of the diseases and disorders associated with misfolded proteins and the associated deposits and plaques of these proteins are diseases and disorders of the central nervous system. Indeed, most of the diseases and disorders are neurodegenerative in nature, causing diminished neural cell function or neural cell death. The mechanisms by which deposits or plaques are formed from the misfolded proteins, and the relationship of deposit or plaque formation to the disease-associated neurodegenerative processes are not well-defined.

[0005] A group of proteins that are among these plaque-forming proteins are the prion proteins. Currently, prion proteins are under intense investigation due to their association with neurodegenerative diseases in farm animals and the human population, and their apparent transmission through biological materials from one animal or human to another, including apparent cross-species transmission.

[0006] It is widely held that prions, which are the infectious agents of neurodegenerative diseases, are, in fact,

entirely proteinaceous, and it has been postulated that the prion protein is the entity known as a prion: The prion protein is a protein referred to as PrP²⁷⁻³⁰ or PrP^C. It is an approximately 28: kilodalton hydrophobic glycoprotein that, when misfolded, aggregates into rod-like filaments found as plaques or deposits in infected brains. Prions exist normally as innocuous cellular proteins. However, prions possess an innate capacity to convert their structure and cause several deadly brain diseases of the dementia type in humans and animals. The dominating hypothesis is that, unlike all other infectious pathogens, infection is caused by an abnormal conformation of the prion protein, which acts as a template and converts normal prion conformations into abnormal conformations.

[0007] Complete prion protein-encoding genes have been cloned, sequenced, and expressed in transgenic animals. PrP^C is encoded by a single-copy cellular gene and is normally found at the outer surface of neurons, attached to the membrane by way of a glycolipid moiety at the C-terminal portion of the protein. Cycling of the protein from the surface to the interior is known to occur, but the function of this cycling is not yet elucidated. Through an as-yet unclear post-translational process, under certain circumstances, PrP^{Sc} is formed from the normal, cellular PrP^C. Neurodegenerative disease then can develop, a process that can take as much as decades to become clinically evident in humans.

[0008] The delay between the time of infection and manifestation of clinical symptoms of neurodegenerative disease is cause for heightened concern because this delay can permit unknowing transmission of the disease from one individual to others. For example, it can permit an animal infected with a prion to be slaughtered, and the potentially infectious products from that animal to enter the animal or human food stream. Likewise, it can permit an infected human to transmit infectious material to others through blood or organ donation. Thus, it is of great interest to the health community, the farming industry, and the general public to monitor animals and animal products (such as meat), and to monitor medical samples derived from humans (such as blood donations and organ donations) to reduce or eliminate the likelihood of transmission of prion proteins from infected individuals to others.

[0009] The normal cellular protein (PrP^C) can be differentiated from the misfolded, infective protein (PrP^{Sc}) by numerous methods, the most common of which being susceptibility or resistance to degradation by proteases, such as Proteinase K, and detection with antibodies raised against one form of the protein or the other, or prior to or after proteinase digestion.

[0010] Many of the current techniques used to detect the presence of prion-related infections rely on gross morphological changes in the brain, or immunochemical techniques that are generally applied only after clinical symptoms are manifest, and which require biopsy material or material taken post mortem. Of course, by the time

gross morphological changes in the brain are evident, a human may have transmitted infectious particles to others through blood donations or donation of organs or tissues. Similarly, by the time post mortem analysis of animal tissue has been completed, products from the animal may have already entered the food stream and potentially infected other animals or even humans.

[0011] Other techniques in development or use rely on catalytic propagation of the misfolded form of cellular proteins involved in neurodegenerative diseases, such as prion protein. For example, Published U.S. Patent Application 2005/0026165 A1 and International Application WO 02/097444 A2 disclosed the use of peptide probes to detect small amounts of misfolded protein in samples. These peptides having sequences that bind to misfolded proteins are exposed to samples suspected of containing the misfolded protein. If misfolded protein is present, the probes bind to the misfolded protein. Binding causes a conformational change in the probe that permits it to bind to other probe molecules. Binding of other probe molecules to the misfolded protein-probe complex causes a conformational change in the newly bound probe, which converts it to a conformation that is capable of binding to yet another probe molecule in the mixture. The design of the probes permits a detectable signal to be generated when the target misfolded protein is present.

[0012] A method for detecting PrP^{Sc} was disclosed by Grosset et al., 2005, in *Peptides*, 26; 2193-2200, published after the priority filing date. Further, synthetic peptides and their formation of peptide aggregates were described by Tcherkasskaya et al., 2003, in *Journal of Biomolecular Structure & Dynamics*, 21(3); 353-365, and methods of making immobilized probes that are specific for prion proteins were disclosed in international application WO 2006/031644, published after the priority filing date of this application.

[0013] Although numerous techniques for detecting misfolded proteins, such as infectious prion proteins, exist in the art, there still exists a need for improved techniques that are rapid, inexpensive, reliable, reproducible, easy to use, and/or provide improved sensitivity. Improving the sensitivity relates to virtually all other needs. Furthermore, there exists a need for this technique to be convenient to carry out by means of a high-throughput kit.

SUMMARY OF THE INVENTION

[0014] The present invention addresses needs in the art, including increasing the detection sensitivity, by providing methods and kits for detection of conformationally-altered proteins, such as prions, which are associated with any number of neurodegenerative diseases and disorders. Conformationally dependent peptides, such as those that are labeled peptides designed to mimic the folding reaction of PrP^C converting to PrP^{Sc} (also known as, and used equivalently for, PrP^{TSE}), provide the basis for a highly sensitive diagnostic assay for misfolded proteins, such as PrP^{Sc}. Superior sensitivity is achieved due

to signal amplification as additional peptides, such as labeled peptides, are recruited in a target-enriched solution to undergo a similar conformational change, enabling the effective detection of the misfolded protein, such as PrP^{Sc}, in the blood or other tissues of animals and humans containing the misfolded proteins, such as those infected with certain PrP^{Sc}-related diseases or those with Alzheimer's disease.

[0015] The present invention relates to a method for detecting the presence or amount of prion protein or A Beta protein in a sample, said method comprising: combining (i) a sample containing or suspected of containing a prion protein or misfolded protein with (ii) a conformational biotin-labeled capture peptide to make a mixture, wherein (ii.1) the conformational capture peptide has a size between 15 and 45 residues, an amino acid sequence that is at least 70% identical to any one of the amino acid sequences selected from SEQ. ID. NOs. 1, 4-35, and 44-58, and (ii.2) interacts with the pathogenic, misfolded form of the prion protein or A Beta protein and assumes a predominantly β -sheet conformation upon association with the protein, (b) incubating the mixture for an amount of time sufficient to form a complex comprising an association of at least one molecule of prion protein or A Beta protein present in the sample and at least one molecule of conformational capture peptide, (c) exposing the mixture to conditions that separate, at least partially, the complex, if present, from at least one other substance in the mixture, wherein the exposing step comprises binding the conformational capture probe, prion protein or A Beta protein, or complex thereof to a solid phase, and (d) detecting the presence or absence of any association between the conformational capture peptide and any prion protein or A Beta protein, as well as kits for carrying out this method.

[0016] The invention also comprises a kit comprising at least one conformational biotin-labeled capture peptide and at least one detection-amplification double-labeled peptide, wherein the conformational capture peptide has a size between 15 and 45 residues, an amino acid sequence that is at least 70% identical to any one of the amino acid sequences selected from SEQ. ID. NOs. 1, 4-35, and 44-58, and interacts with the pathogenic, misfolded form of a prion protein or an A Beta protein and assumes a predominantly β -sheet conformation upon association with the prion protein or A Beta protein, and further comprising a solid phase capable of binding the conformational capture probe, prion protein or A Beta protein, or complex thereof.

[0017] Among the many uses for the invention, the methods and kits can be used to screen samples from humans or animals for the presence of misfolded proteins. In addition, the methods and kits can be used for diagnostic purposes, such as to diagnose an animal or human as having a disease or disorder associated with a misfolded protein, such as a prion protein. The methods and kits can further be used to monitor the amount of misfolded protein in an individual over time. In general,

the methods and kits can be used with any probe or set of probes that permits catalytic propagation of misfolded protein conformation in a sample containing a misfolded protein. Thus, the methods and kits are broadly applicable to detection of numerous diseases and disorders, particularly those of a neurodegenerative nature.

BRIEF DESCRIPTION OF THE FIGURES

[0018] Figure 1 depicts generally a catalytic-propagation assay used according to the invention.

[0019] Figure 2 depicts results of a standard catalytic-propagation assay used in the invention.

[0020] Figure 3 depicts results of chromatographic separation of complexes of probe and misfolded-prion protein according to the method of the invention.

[0021] Figure 4 depicts results of a standard catalytic-propagation assay for enriched sheep plasma, including PBS control, as practiced by the invention.

[0022] Figure 5 depicts results of the selective-capture embodiment of the invention, with human plasma samples.

[0023] Figure 6 depicts a protocol dose response for selective-capture misfolded-protein diagnostics (MPD).

[0024] Figure 7 depicts results of selective capture with sheep serum samples.

[0025] Figure 8 depicts the effect of sequential washings of captured sCJD substrate from a solid phase comprising magnetic beads.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

[0026] The present disclosure describes methods and kits for detection of misfolded proteins in samples. Unless otherwise noted, all terms used herein have their customary meaning within the biotechnology, protein biochemistry, and medical diagnostics fields.

[0027] As used herein, and consistent with use in the scientific literature, the terms "prion" and "prion protein" are used interchangeably to indicate the proteinaceous material that causes neurodegenerative disease states in animals and humans. Prion and prion protein are used interchangeably to indicate both the normal cellular conformation of a protein and the infectious or disease-causing conformation. Where helpful for clarity, the particular form is used: PrP^C for normal cellular conformation or PrP^{Sc} for disease-causing conformation.

[0028] The terms "prion", "prion protein", and the like are used interchangeably herein to refer to the infectious PrP^{Sc} form of a PrP protein. Particles are comprised largely, if not exclusively, of PrP^{Sc} molecules encoded by a PrP gene. Prions are distinct from bacteria, viruses, and viroids. Known prions infect animals and cause Scrapie, a transmissible, degenerative disease of the nervous system of sheep and goats, as well as bovine spongiform encephalopathy (BSE), or "mad cow disease", and feline spongiform encephalopathy of cats.

Four prion diseases known to affect humans are (1) kuru, (2) Creutzfeldt-Jakob Disease (CJD), (3) Gerstmann-Straussler-Scheinker Disease (GSS), and (4) fatal familial insomnia (FFI). As used herein "prion" includes all forms of prions causing all or any of these diseases or others in any animals, in particular in humans and domesticated farm animals.

[0029] "Protein" refers to any polymer of two or more individual amino acids (whether or not naturally occurring) linked via a peptide bond, and occurs when the carboxyl carbon atom of the carboxylic acid group bonded to the α -carbon of one amino acid (or amino acid residue) becomes covalently bound to the amino nitrogen atom of the amino group bonded to the α -carbon of an adjacent amino acid. These peptide bond linkages, and the atoms comprising them (*i.e.*, α -carbon atoms, carboxylcarbon atoms (and their substituent oxygen atoms), and amino nitrogen atoms (and their substituent hydrogen atoms)) form the polypeptide backbone of the protein.

[0030] The term "protein" is understood to include the terms "polypeptide" and "peptide" (which may be used interchangeably herein) within its meaning. In addition, proteins comprising multiple polypeptide subunits or other components (for example, an RNA molecule, as occurs in telomerase) will also be understood to be included within the meaning of "protein" as used herein. Similarly, fragments of proteins and polypeptides are also within the scope of the invention and may be referred to herein as "proteins".

[0031] "Conformation" refers to the presence of a particular protein conformation, for example, an α -helix, parallel and antiparallel β -strands, leucine zipper, zinc finger, etc. In addition, conformational constraints can include amino acid sequence information without additional structural information. A "conformational change" is a change from one conformation to another.

[0032] "Conformationally altered proteins" are all proteins that have a single primary amino acid sequence, but that can exist in an individual or *in vitro* in both a normal three-dimensional conformation and a three-dimensional conformation that is associated with a disease. The conformationally altered protein can be associated with the disease in any detectable way. For example, it can cause the disease, can be a factor in a symptom of the disease, or can be present in a biological sample or *in vivo* as a result of other substances that cause the disease or are a result of the disease. Conformationally altered proteins have both normal conformations and various misfolded conformations.

[0033] The exact mechanism by which the sequence of a protein encodes the proper fold is unknown. In order to achieve the native state encoded by the fold, the protein molecule must convert to a unique conformation selected from many alternatives. Functional proteins are typically soluble and can adopt a variety of structures including coils and ordered elements. Ordered elements include the α -helix predominant in proteins such as myoglobin and hemoglobin. During the human aging proc-

ess, in some proteins the soluble structure (*e.g.*, α -helical regions) becomes conformationally altered into β -sheet structures that undergo aggregation associated with loss of function.

[0034] "Conformational probes" are peptides that have amino acid sequences that are sufficiently similar to sequences present in a target misfolded protein to permit association (by any known means, such as hydrophobic interaction or van der Waals interaction) between the probe and target protein. Association of a conformational probe to a misfolded protein causes the probe (or a portion of the probe molecules present) to change conformation to a second conformation, which is different from the conformation in which it existed when exposed to the misfolded protein. Although not required, conformational probes may assume a predominantly β -sheet conformation upon association with the misfolded protein. Conformational probes can be, but are not necessarily, labeled with a detectable label, such as a fluorescent moiety.

[0035] "Labels" refer to molecules capable of detection, including radioactive isotopes, fluorescers, luminescers, chemiluminescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands such as biotin, and the like. The term "fluorescer" refers to a substance or a portion thereof that is capable of exhibiting fluorescence in the detectable range. Particular examples of labels that may be used with the invention include, but are not limited to fluorescein, rhodamine, dansyl, umbelliferone, Texas red, luminol, acradimium esters, NADPH, β -galactosidase, horseradish peroxidase, glucose oxidase, alkaline phosphatase and urease. The label can also be an epitope tag (*e.g.*, a His-His tag), an antibody or a detectable oligonucleotide.

[0036] There are at least twenty proteins that are associated with human disease when they adopt a conformationally altered state. The normal wild-type form of prion protein (PrP^C) prefers a monomeric state, while the abnormal, disease-causing form (PrP^{Sc}) more readily takes on a multimeric state. The present invention, while focusing on prion detection, is equally applicable to all diseases and disorders associated with proteins that adopt a conformationally altered state.

[0037] Protein structures can be determined by a variety of experimental or computational methods, several of which are described below. Protein structure can be assessed experimentally by any method capable of producing at least low-resolution structures. Such methods currently include X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. NMR enables determination of the solution conformation (rather than crystal structure) of biomolecules. Generally, biomolecule structures determined by NMR spectroscopy are of moderate resolution compared to those determined by crystallography. Other techniques useful in studying biomolecule structure include circular dichroism (CD), fluorescence, and ultraviolet-visible absorbance spectroscopy. See, for example, Physical Biochemistry: Applications to

Biochemistry and Molecular Biology, Second Ed., W.H. Freeman & Co., New York, NY, 1982 for descriptions of these techniques. Any suitable technique can be used in accordance with the present invention.

[0038] "Equivalent" refers to amino acid sequences that are similar in sequence to the amino acid sequence of the protein to be analyzed but have at least one, but fewer than five, differences, substitutions, additions, or deletions. Thus, the substitution of one or more amino acid in a given sequence which does not substantially change the basic function of that amino acid, is equivalent for purposes of describing the present invention.

[0039] "Homology", "homologs of", "homologous", "identity", and "similarity" refer to sequence similarity between two peptides, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid, then the molecules are identical at that position. A degree of identity of amino acid sequences is a function of the number of identical amino acids at positions shared by the amino acid sequences. A degree of homology or similarity of amino acid sequences is a function of the number of amino acids, *i. e.*, structurally related, at positions shared by the amino acid sequences. A "non-homologous" sequence shares less than 40% identity, though preferably less than 25% identity, with one of the sequences used in the present invention. Related sequences share more than 40% identity, preferably at least about 50% identity, more preferably at least about 70% identity, even more preferably at least about 90% identity; and most preferably at least about 99% identity.

[0040] The term "percent identical" refers to sequence identity between two amino acid sequences. Identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same amino acid, then the molecules are identical at that position; when the equivalent site is occupied by the same or a similar amino acid residue (*e.g.*, similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology, similarity, or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. Various alignment algorithms and/or programs may be used, including FASTA, BLAST, or ENTREZ. FASTA and BLAST are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, WI), and can be used with, *e.g.*, default settings. ENTREZ is available through the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD.

[0041] The terms "interact" and "bind" as used herein mean detectable interactions (*e.g.*, biochemical interactions) between molecules, such as interaction between

protein-protein, protein-nucleic acid, nucleic acid-nucleic acid, and protein-small molecule or nucleic acid-small molecule in nature.

[0042] Unless otherwise indicated, the practice of the present invention will employ conventional methods of chemistry, biochemistry, molecular biology, immunology, medicine, and pharmacology, within the skill of the art. Such techniques can be understood by referring to the current the literature, such as for example *Methods in Enzymology* Vol. 278: Fluorescence Spectroscopy (L. Brand and M.L. Johnson, Eds., Academic Press, Inc., 1997); *Methods in Enzymology* Vol. 309: Amyloid, Prions and Other Protein Aggregates (R. Wetzel, Ed., Academic Press, Inc., 1999); *Handbook of Experimental Immunology*, Vols. I-IV (D. M. Weir and C. C. Blackwell, Eds., 1986, Blackwell Scientific Publications); and *Handbook of Surface and Colloidal Chemistry* (Birdi, K. S., Ed., CRC Press, 1997).

[0043] In a first aspect of the invention, methods of detecting the presence and/or amount of a misfolded protein in a sample are provided. In general, the methods comprise providing a sample containing or suspected of containing a misfolded protein, such as a prion; providing at least one conformational probe; combining the sample with the conformational probe to make a mixture; incubating the mixture for an amount of time sufficient for an association of at least one molecule of misfolded protein and at least one molecule of probe to form a complex; exposing the mixture to an environment that separates, at least partially, the complex from at least one other substance in the mixture; and detecting the presence or absence of an association between at least one probe and the misfolded protein, wherein said detecting is preferably, enhanced by addition of a second conformational probe to amplify the analytical signal. Of course, in the various embodiments of the present invention, these steps may be performed in different orders to achieve the desired goals.

[0044] In accordance with the methods of the invention, providing can be any activity that results in a sample containing or suspected of containing a misfolded protein, or containing a conformational probe being present and available for use in the method. Thus, providing can comprise removal of a tissue, organ, body part, or liquid from an individual. Likewise, it can comprise obtaining a biological sample, such as blood or meat, from an individual, company, or government agency that obtained the sample. In addition, it can comprise taking a sample obtained from an individual and processing it in some way, such as to eliminate one or more biological or other substances. Although processing of the sample prior to combining it with the probe is encompassed by the invention, in some embodiments, such processing is not performed. With regard to providing of at least one conformational probe, such providing can comprise synthesizing, using any suitable technique, one or more conformational probes, obtaining one or more probes synthesized by another, and obtaining a mixture of two or

more probes, or at least one probe and contaminating substances, then purifying the probe, at least to some extent, from the contaminants.

[0045] The sample can be any sample containing or suspected of containing a misfolded protein. A sample that is suspected of containing a misfolded protein can be any sample taken from any animal or human in which a disease or disorder associated with a misfolded protein exists. Thus, the level of suspicion need not be high; it is simply enough to know or suspect that the individual from whom the sample was taken was in a population at risk of suffering from one of the diseases or disorders associated with a misfolded protein. Examples of samples include, but are not limited to, blood or blood products or blood by-products; neural tissue, including, but not limited to brain tissue; meat or meat by-products; skin or skin products (including mucous membranes); intestine casings; milk; and urine.

[0046] In certain embodiments, one or more control reactions are performed in parallel with the method of detecting a misfolded protein. In these embodiments, the control reactions are considered as part of the method even though they can be, but are not necessarily, run in separate reaction containers. Control reactions can be positive controls or negative controls. Any number of controls can be run to identify and monitor the performance of any step or any component used in the method. In certain positive controls, the sample provided is known to have at least one misfolded protein, and thus is used to monitor the success and, where appropriate, sensitivity of the reaction. In certain negative controls, the sample is known not to contain a misfolded protein (*e.g.*, distilled water or water-based buffer). Furthermore, in certain embodiments, a series of control reactions are performed to obtain a standard curve against which the sample of interest is compared. As is known in the art for other assays to detect substances in samples, control reactions can be performed before the method for detecting misfolded protein, at the same time as the method for detecting misfolded protein, or after the method for detecting misfolded protein.

[0047] The conformational probe can be any probe that satisfies the criteria set forth above. Various suitable exemplary probes are disclosed in Published U.S. Patent Application 2005/0026165 A1. Preferable conformational probe are disclosed herein, below. The conformational probe can be provided as a single probe (*i.e.*, a collection of identical peptides, all having the same amino acid sequence) or can comprise multiple different probes (*i.e.*, a collection of two or more peptides having different amino acid sequences, each peptide being present in multiple copies). According to the invention the conformational probe(s) is labeled with a moiety that is detectable. Examples of detectable labels include, but are not limited to, luminescent labels, fluorescent labels, radioactive labels, and immunogenic labels.

[0048] The probes can be provided in any form, including, but not limited to, purified solutions in water, dried

powders, or dispersions in aqueous or organic liquids. Thus, they can be provided in compositions comprising purified probe alone, a mixture of purified probes of different sequences, or unpurified probe or mixtures of probes with one or more non-probe substances (*e.g.*, buffers, liquids, or detection reagents). Probes can comprise a single label or multiple labels. In certain embodiments, two or more labels are provided on each probe. For example, a probe of the invention can comprise a label attached to each end of the probe (N-terminus and C-terminus). In some embodiments, the conformational change in the probe upon associating with the target misfolded protein causes the two labels to come into close proximity, which enhances the signal generated from the probes as compared to the signals generated when the probes are not in close proximity.

[0049] According to the method, combining can be any action that causes at least a portion of the sample and at least a portion of the composition comprising the probe(s) to form a single composition. As used in the method, this single composition is referred to as a mixture; however, any single composition comprising the two components is encompassed by the terminology. Thus, combining can comprise adding a liquid composition of probe(s) to the sample or vice versa. Likewise, it can comprise adding a dried composition of probe(s) to sample or vice versa. The mixture so formed can be subjected to conditions that cause the two compositions to fully combine with each other (*e.g.*, centrifugation, shaking, or pipetting) or the two compositions can simply be added to one another and permitted to mix through simple diffusion, dissolution, etc. It is not critical how the sample and probe(s) be combined as long as the two are permitted to contact each other such that at least one probe can contact at least one misfolded protein, if present.

[0050] The method includes incubating the probe(s) and sample for an amount of time sufficient for an association of at least one molecule of misfolded protein and at least one molecule of probe to form a complex. The time of incubation will vary based on known physical properties, such as concentration of probe(s) and/or misfolded protein, temperature, presence or absence of substances that inhibit or promote interaction of proteins and peptides, and the like. Routine experimentation can be carried out by a person of ordinary skill in the art, practicing this invention, in order to understand the impacts of various system parameters on the incubation time.

[0051] The method of the invention comprises exposing the mixture of the sample and the probe(s) to conditions that separate, at least partially, complexes of probe and misfolded protein, if present, from at least one other substance in the mixture. This separation step can be performed after the incubation step, concurrent with the incubation step, or partially concurrently with the incubation step.

[0052] In embodiments wherein incubation and separation are concurrent, certain benefits can arise. Isolation is performed as the association between the probe and

target protein is occurring, thereby reducing the time required to detect the presence of misfolded protein, and eliminating steps and reagents needed to detect the presence of misfolded protein. Rapid detection of complexes of probe and target misfolded protein is possible because complexes of probe and target misfolded protein will typically be high-molecular weight entities having unique or unusual properties (typically due to the high levels of β -sheet structures present). The complexes can be isolated, at least partially, from other substances in the mixture using rapid, well-characterized techniques, such as size-exclusion chromatography or filtration.

[0053] Furthermore, incubating and separating at the same time permits high sensitivity. That is, because the mixture is separated into two or more fractions prior to detection, and the separation technique used is preferably chosen based on characteristics that remove substances that interfere with signal generation or detection, fractions containing probe-misfolded protein complexes will have signal-to-noise ratios that are improved over the original mixture. Because the fraction containing the probe-misfolded protein complex will be devoid or essentially devoid of interfering substances, the amount of signal needed to detect the presence of the complexes will be less than needed in the mixture itself.

[0054] As described herein the separating can be accomplished by any suitable technique. One convenient physical characteristic of complexes of probe and misfolded protein is typically their large mass. Thus, a suitable technique for separation may take advantage of the size of the complexes, and can include filtration or size-exclusion chromatography. Other physical characteristics that can be taken advantage of will be apparent to those of skill in the art, and can include solubility or hydrophobicity under various conditions, or affinity to a particular stationary phase, for example. Separating can also comprise binding of the probe, target polypeptide, or complex to a solid support, such as a magnetic bead, and relying, at least in part, on the properties of the solid support to achieve separation.

[0055] The methods of the invention include detecting the presence of probes associated with misfolded proteins. Detecting can be accomplished by any means known in the art for detecting protein-protein interactions. In some embodiments, the probes are labeled, and detection is by way of detecting a signal generated by a probe associated with a misfolded protein. In some embodiments, the probe includes two signal-generating moieties whose signals are enhanced when brought into close proximity. In these embodiments, the amino acid sequences of the probes are designed such that binding of the probes to a misfolded protein brings the two signal-generating moieties into close proximity.

[0056] The invention generally includes peptides that interact preferentially with pathogenic forms of a misfolded protein. In certain embodiments, the peptides described herein interact preferentially with pathogenic forms of a prion as compared to non-pathogenic forms

of the prion. Using preferred embodiments of this invention, high sensitivities can be achieved. Examples of suitable peptides that achieve high sensitivities include those described herein. In certain embodiments, peptides interact preferentially with PrP^{Sc} as compared to PrP^C. The peptides may be specific for PrP^{Sc} from a single species or from multiple species.

[0057] One or more biotin labeled peptides of the invention are added to capture the pathogenic prion by forming a complex between the peptide(s) and the pathogenic misfolded protein or prion. This complex is then enriched in the sample by means of a solid phase comprising one or more properties imparting a capability to separate, at least partially, the complex from at least one other component of the sample, preferably from substantially all of the rest of the sample, which is not bound to the solid phase. The solid phase, which contains at least some target complex, is then enriched (pulled down) using a solvent-containing composition, such as phosphate-buffered saline (PBS), and which preferably comprises an additional detectably double-labeled peptide sometimes called herein a detection-amplification peptide, to amplify the signal to some extent and add at least some additional sensitivity to the overall detection method. For example, the solid phase, which contains at least some of the target complex, is then enriched (pulled down) from the sample with either a centrifugation step or through the use of a magnet in the case of the solid phase being magnetic beads. Once the immobilized target complex is enriched from the sample, the interference contributed by the remaining sample can be removed using a standard micropipette. The immobilized target complex can then be washed using standard wash buffer, such as phosphate-buffered saline (PBS), to further remove contaminating or interfering substances present in the original sample. Then, the immobilized target complex, which contains both the target as well as the capture peptide, is resuspended into distilled water and/or PBS and the detection-amplification double-labeled peptide is added to increase the specificity of the overall detection method.

[0058] In some preferred embodiments, the sample is plasma or serum. The capture peptide is a biotin end-labeled prion probe:

Biotin-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV (SEQ. ID. NO. 1)

The solid phase is streptavidin-coated magnetic beads, which is effective to enrich the concentration of the peptide-misfolded protein complex in the sample. The detection-amplification peptide is labeled with pyrene on both ends:

Pyrene-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-Pyrene (SEQ. ID. NO. 2)

Extrinsic fluors such as pyrene allow detection of confor-

mational changes using common fluorescence detection techniques. Optionally, an extra lysine residue is present at one end of the peptide to increase the effectiveness of the pyrene label:

Pyrene-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-K-Pyrene (SEQ. ID. NO. 3)

[0059] Effective embodiments of the capture peptide for prions include at least the following sequences:

Biotin-KPKTNMKHVAGAAVV-OH (SEQ. ID. NO. 4)
Biotin-GGGKPKTNMKHVAGAAAAGAVV-OH
(SEQ. ID. NO. 5)

Biotin-PPPKPKTNMKHVAGAAAAGAVV-OH
(SEQ. ID. NO. 6)

Biotin-RRRKPKTNMVAGAAAAGAVV-OH (SEQ.
ID. NO. 7)

Biotin-KKKKPKTNMKHVAGAAAAGAVV-OH (SEQ.
ID. NO. 8)

H₂N-KPKTNMKHVAGAAAAGAVV-Biotin (SEQ. ID.
NO. 9)

H₂N-KPKTNMKHVAGAAAAGAVVGGG-Biotin
(SEQ. ID. NO. 10)

H₂N-KPKTNMKHVAGAAAAGAVVPPP-Biotin
(SEQ. ID. NO. 11)

H₂N-KPKTNMKHVAGAAAAGAVVRRR-Biotin
(SEQ. ID. NO. 12)

H₂N-KPKTNMKHVAGAAAAGAVVKKK-Biotin
(SEQ. ID. NO. 13)

Biotin-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-OH (SEQ. ID. NO. 14)

Biotin-GGGVVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-OH (SEQ. ID. NO. 15)

Biotin-PPPVVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-OH (SEQ. ID. NO. 16)

Biotin-RRRVVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-OH (SEQ. ID. NO. 17)

Biotin-KKKVVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-OH (SEQ. ID. NO. 18)

Biotin DVVDAGAADAAGAVHKMNTKPKMKHVA-
GAADAAGADVVK-OH (SEQ. ID. NO. 19)

Biotin-KPKTNLKHVAGAAAAGAVV-OH (SEQ. ID.
NO. 20)

Biotin-GGGKPKTNLKHVAGAAAAGAVV-OH
(SEQ. ID. NO. 21)

Biotin-PPPKPKTNLKHVAGAAAAGAVV-OH (SEQ.
ID. NO. 22)

Biotin-RRRKPKTNLKHVAGAAAAGAVV-OH (SEQ.
ID. NO. 23)

Biotin-KKKKPKTNLKHVAGAAAAGAVV-OH (SEQ.
ID. NO. 24)

H₂N-KPKTNLKHVAGAAAAGAVV-Biotin (SEQ. ID.
NO. 25)

H₂N-KPKTNLKHVAGAAAAGAVVGGG-Biotin
(SEQ. ID. NO. 26)

H₂N-KPKTNLKHVAGAAAAGAVVPPP-Biotin
(SEQ. ID. NO. 27)

H₂N-KPKTNLKHVAGAAAAGAVVRRR-Biotin

(SEQ.ID.NO.28)

H₂N-KPKTNLKHVAGAAAAGAVVKKK-Biotin

(SEQ. ID. NO. 29)

Biotin-VVAGAAAAGAVHKLNTKPKLKHVA-

GAAAAGAVV-OH (SEQ. ID. NO. 30)

Biotin-GGGVVAGAAAAGAVHKLNTKPKLKHVA-

GAAAAGAVV-OH (SEQ. ID. NO. 31)

Biotin-PPPVVAGAAAAGAVHKLNTKPKLKHVA-

GAAAAGAVV-OH (SEQ. ID. NO. 32)

Biotin-RRRVVAGAAAAGAVHKLNTKPKLKHVA-

GAAAAGAVV-OH (SEQ. ID. NO. 33)

Biotin-KKKVVAGAAAAGAVHKLNTKPKLKHVA-

GAAAAGAVV-OH (SEQ. ID. NO. 34)

Biotin-DVVDAGAADAAGAVHKLNTKPKLKHVA-

GAADAAGADVVK-OH (SEQ. ID. NO. 35)

[0060] Effective embodiments of the detection-amplification peptide for prions include at least the following sequences:

Pyr-DVVDAGAADAAGAVHKMNTKPKMKHVA-

GAADAAGADVVK-Pyr (SEQ. ID. NO. 36)

Pyr-VVAGAAAAGAVHKMNTKPKMKHVAGAAA-

GAVV-Pyr (SEQ. ID. NO. 37)

Pyr-DVVDAGAADAAGAVHKLNTKPKLKHVA-

GAADAAGADVVK-Pyr (SEQ. ID. NO. 38)

Pyr-VVAGAAAAGAVHKLNTKPKLKHVAGAAA-

GAVV-Pyr (SEQ. ID. NO. 39)

Pyr-DVVDAGAADAAGAVHKMNTKPKMKHVA-

GAADAAGADVVK-Pyr (SEQ. ID. NO. 40)

Pyr-VVAGAAAAGAVHKMNTKPKMKHVAGAAA-

GAVVK-Pyr (SEQ. ID. NO. 41)

Pyr-DVVDAGAADAAGAVHKLNTKPKLKHVA-

GAADAAGADVVK-Pyr (SEQ. ID. NO. 42)

Pyr-VVAGAAAAGAVHKLNTKPKLKHVAGAAA-

GAVVK-Pyr (SEQ. ID. NO. 43)

where Pyr is pyrene.

[0061] When the target protein is A Beta, effective embodiments of the capture peptide include at least the following sequences:

Biotin-KLVFFAEDVGSNKGAIIGLMK-OH (SEQ. ID. NO. 44)

Biotin-GGGKLVFFAEDVGSNKGAIIGLMK-OH (SEQ. ID. NO. 45)

Biotin-PPPKLVFFAEDVGSNKGAIIGLMK-OH (SEQ. ID. NO. 46)

Biotin-RRRKLVFFAEDVGSNKGAIIGLMK-OH (SEQ. ID. NO. 47)

Biotin-KKKKLVFFAEDVGSNKGAIIGLMK-OH (SEQ. ID. NO. 48)

H₂N-KLVFFAEDVGSNKGAIIGLMKGGG-Biotin (SEQ. ID. NO. 49)

H₂N-KLVVFFAEDVGSNKGAIIGLMKPPP-Biotin (SEQ. ID. NO. 50)

H₂N-KLVFFAEDVGSNKGAIIGLMKRRR-Biotin

(SEQ. ID. NO. 51)

H₂N-KLVFFAEDVGSNKGAIIGLMK-KK-Biotin

(SEQ. ID. NO. 52)

5 **[0062]** While the embodiments described herein are preferable, other similarly effective embodiments exist for probe composition, labels for the detection-amplification peptides, solid-phase composition and activity, and sample origin and type. It will be understood by those skilled in the art that a variety of labels and solid phases could be employed, depending on the specific analytical technique used. Analogs and derivatives of peptides can be effective.

10 **[0063]** Peptide derivatives can also include modifications to the native sequence, such as deletions, additions, and substitutions, provided the peptide substantially maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis of the corresponding gene sequence, or may be accidental, such as through mutations of hosts that produce the proteins or errors due to PCR amplification. Furthermore, modifications may be made that have one or more of the following effects: reducing toxicity; increasing affinity and/or specificity for prions; facilitating cell processing; and facilitating presentation to B-cells and/or T-cells. Polypeptides described herein can be made in a variety of ways as in known in the art, including recombinant techniques, synthesis, purification from natural sources, or from tissue culture.

20 **[0064]** The capture peptides and detection-amplification peptides of the invention can be anywhere from about 10 to about 100 residues long, preferably from about 10 to 50 residues, more preferably from about 15 to about 45 residues. For example, they may be between 15 and 35 residues, 20 and 35 residues, 20 and 30 residues, 25 and 35 residues, 30 and 50 residues, any number or range of residues having at least 10 residues, and any number or range of residues having no more than 100 residues. One of ordinary skill in the art will understand that any specific residue length within these ranges is encompassed within the invention.

30 **[0065]** Analogs of the labels can also be used. To illustrate, the detection-amplification peptides can be doubly labeled with different fluorescent moieties than pyrene, such as pyrene butyrate, succinimidyl 1-pyrene, riboflavin, rosolic acid, 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid, acridine, 4-amino-N-[3-vinylsulfonyl] phenyl] naphth-alimide-3,5 disulfonate, anthranilamide, coumarin, cyanosine, 4',6-diaminidino-2-phenylindole (DAPI), diethylenetriamine pentaacetate, 4,4'- diisothiocyanatodi- hydro- stilbene- 2,2'- disulfonic acid, eosin, eosin isothiocyanate, erythrosin, erythrosin B, isothiocyanate, ethidium, fluorescein, 5-carboxyfluorescein (FAM), fluorescein, fluorescein isothiocyanate, 50 fluorescein, nitrotyrosine, pararosaniline, Phenol Red, B-phycoerythrin, or o-phthaldialdehyde. Preferred labels will form an excimeric state, enabling convenient signal detection.

[0066] In the methods using a solid phase described herein, the solid phase can be one or more of cellulose, modified cellulose, or another material derived from lignocellulosic biomass; polystyrene; polypropylene; polyethylene; polylactide; polyacrylamide; silicon; rubber; polysaccharides; latex; polyvinyl fluoride; nylon; polyvinylchloride; polycarbonate; starch; dextran; chitin; sand; silica; pumice; agarose; glass; metal; and any such materials in any form (such as particles, beads, planar surfaces, rods, and the like) and with any surface or bulk modification or activation such as one or more modifications selected from the group consisting of surface roughening, polarity induction, acid or base site generation, magnetic induction, thermal treatment, modification of hydrophobicity, and coating of various types. The solid phase can be particulate or can be in the form of a continuous surface and includes membranes, mesh, plates, pellets, slides, disks, capillaries, hollow fibers, needles, pins, chips, solid fibers, gels, and beads. A specific solid phase may include many elements as discussed herein, *e.g.* magnetically active beads coated with streptavidin or glass particles coated with a hydrophobic polymer.

[0067] The capture peptide is labeled with biotin (single label on either end or both ends of the peptide) and the solid phase preferably comprises magnetic beads coated with streptavidin. The streptavidin is a preferred protein coating for the solid phase; yet one skilled in the art will recognize that it is not the only protein that could be utilized. For example, modifications could be made to streptavidin to alter its ligand-binding specificity, including its biotin-binding specificity, to be higher or lower for any certain ligand of interest. Biotin analogs that could be used include at least 2-iminobiotin and diaminobiotin.

[0068] Although the biotin-streptavidin binding pair is particularly effective, many other binding pairs are operative. Other binding pairs described herein are biotin-avidin, antigen-antibody, hapten-antibody, mimetope-antibody, receptor-hormone, receptor-ligand, agonist-antagonist, lectin-carbohydrate, enzyme-substrate or enzyme-substrate analog, and Protein A-antibody Fc.

[0069] For embodiments utilizing both a biotin-labeled capture peptide and a detection-amplification peptide, the first and second peptides can be substantially the same or different. "Substantially the same" means that the first and second peptide reagents may differ only in the detectable label in these peptide reagents. The capture peptide and the detection-amplification peptide can be derived from peptide fragments from the same region of a prion or from peptide fragments from a different region of a prion. The first peptide reagent and the second peptide reagent can each be independently selected.

[0070] Any suitable means of detection can be used in this invention. In embodiments comprising assays involving the use of labeled peptides, detectable labels suitable for use in the invention include any molecule capable of detection, including radioactive isotopes, fluorophores, chemiluminescers, chromophores, fluorescent semiconductor nanocrystals, enzymes, enzyme sub-

strates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands (*e.g.*, biotin, streptavidin or haptens) and the like. Additional labels include, but are not limited to, those that use fluorescence, including those substances or portions thereof that are capable of exhibiting fluorescence in the detectable range. Particular examples of labels that may be used in the invention include horse radish peroxidase (HRP), fluorescein, FITC, rhodamine, dansyl, umbelliferone, dimethyl acridinium ester (DMAE), Texas red, luminol, NADPH and β -galactosidase. In addition, the detectable label may include an oligonucleotide tag, which can be detected by any known method of nucleic acid detection including PCR, TMA, b-DNA, and NASBA.

[0071] The moiety or chemical entity may be complexed or covalently bonded at or near the amino or carboxy end of the peptide, which is preferably endcapped with a short, hydrophobic peptide sequence. In preferred aspects of the present invention, both the amino and carboxy ends of the probe peptides are endcapped with small hydrophobic peptides ranging in size from about 1 to about 5 amino acids. These may be natural or synthetic, but are preferably natural (*i.e.*, derived from a β -sheet formation region of a target protein). The fluorophores are preferably attached at or near the amino and/or carboxy end of the probe (preferably both) and may be, for example, pyrene, tryptophan, fluorescein, or rhodamine. It is preferable that the fluorophores form excimers when in the correct geometric orientation.

[0072] An "excimer" is an adduct that is not necessarily covalent and that is formed between a molecular entity that has been excited by a photon and an identical unexcited molecular entity. The adduct is transient in nature and exists until it fluoresces by emission of a photon. It is possible to recognize an excimer (or the formation of an excimer) by the production of a new fluorescent band at a wavelength that is longer than that of the usual emission spectrum. An excimer can be distinguished from fluorescence-resonance energy transfer since the excitation spectrum is identical to that of the monomer. The formation of the excimer is dependent on the geometric alignment of the fluorophores and is heavily influenced by the distance between them.

[0073] Preferred conformational transition following interaction with an analyte target is achieved by measuring fluorescence spectra under conditions where excimer formation can be analyzed. Typically, using pyrene as an exemplary fluorophore, the excitation wavelength would be about 350 nm and the observation wavelength 365-600 nm. The normal emission of monomer pyrene following excitation (simple fluorescence) is recorded as the maximum wavelength between about 370-385 nm.

[0074] The methods of the invention can be qualitative, semi-quantitative, or quantitative. Where the methods are practiced semi-quantitatively or quantitatively, they can further comprise generating one or more standard curves of misfolded protein concentrations in the sample of interest, then comparing the results obtained from the

test sample to the standard curve(s). One skilled in the art, by referring to the teachings herein and to standard experimental methodologies, will understand how to practice the invention essentially qualitatively, essentially quantitatively, or semi-quantitatively, depending on the needs of the assay for the particular sample of interest.

[0075] In other aspects of the invention, the detection methods may be used in connection with methods for diagnosing prion-related diseases in human or non-human animal subjects; ensuring a substantially PrP^{Sc}-free blood supply, blood-products supply, or food supply; analyzing organ and tissue samples for transplantation; and monitoring the decontamination of medical equipment. The method comprises the steps of detecting prions in samples of blood (*e.g.*, whole blood, plasma, platelets or serum) from collected blood samples by any of the methods described herein; eliminating any sample in which pathogenic prions are detected; and combining samples where pathogenic prions are not detected to provide a blood supply substantially free of pathogenic prions. Also described herein is a method that can omit the detection step, *per se*, by merely practicing the method by binding misfolded proteins with probe and removing the probe-protein complexes. As a general matter, the amount of protein removed can be expressed in many ways, such as by percent removal, log units removed, or relative amount removed (*e.g.*, fold reduction). For example, when practiced on TSE proteins or particles, the method can achieve a certain log units of infectivity removed, such as at least or about 3 log units of infectivity removed, at least or about 2 log units of activity removed, or at least or about 1 log unit of infectivity removed. When practiced on spiked samples, the method preferably provides an at least 3 log unit reduction in infectivity. Alternatively, in endemic samples, the method preferably results in a sample having below 2 log units of infectivity, more preferably below 1 log unit of infectivity. Another way to express the amount of target material removed is by reference to a percent removal. In embodiments, the method can remove at least 25% of the target protein, at least 40% of the target protein, at least 50% of the target protein, at least 60% of the target protein, at least 65% of the target protein, at least 75% of the target protein, at least 80% of the target protein, at least 85% of the target protein, at least 90% of the target protein, at least 95% of the target protein, at least 98% of the target protein, or at least 99% or more of the target protein, such as at least 99.5%, 99.9%, and 99.99% of the target protein.

[0076] Also described herein are methods of preparing a food supply that is substantially free of pathogenic prions, comprising the steps of detecting prions, using any of the methods of detection described herein, samples collected from live or dead organisms that will enter the food supply or samples collected from food intended to enter the food supply; identifying samples in which pathogenic prions are detected; and removing from the food supply any live or dead organism or food intended to enter the food supply, in samples from which pathogenic

prions are detected. Such a food supply is substantially free of pathogenic prions.

[0077] In other aspects, the present invention provides a method for substantially removing pathogenic misfolded proteins and prions from a sample. This method comprises providing a capture peptide of the invention, a solid phase of the invention, and one or more detection-amplification peptides of the invention. A sample suspected of containing misfolded proteins or prions is incubated with a preferred peptide that gives a high capture rate, followed by contacting with a preferred solid phase for a period of time whereby the complex formed between the capture peptide and the misfolded protein or prion, if present, is enriched from the sample. This technique can be optimized to achieve a desired removal efficiency for the misfolded proteins or prions, wherein monitoring of the efficiency can be conveniently carried out by adding a preferred double-labeled peptide to the pull-down phase, such that an analytical technique will monitor decrease in concentration of misfolded proteins or prions over time.

[0078] In any of the methods described herein the sample can be a biological sample obtained or derived from a living or once-living organism, such as organs, whole blood, blood fractions, blood components, plasma, platelets, serum, cerebrospinal fluid (CSF), brain tissue, nervous system tissue, muscle tissue, bone marrow, urine, tears, non-nervous system tissue, organs, and/or biopsies or necropsies. In preferred embodiments, the biological sample comprises blood, blood fractions or blood components.

[0079] In another aspect, the present invention provides kits for performing the methods of the invention. In some embodiments, the kits are diagnostic kits for diagnosing the presence of at least one misfolded protein in a sample, and thus a disease or disorder associated with at least one misfolded protein. In other embodiments, the kits are detection kits for screening human medical products, such as blood, organs, or tissues, for the presence of misfolded proteins associated with a disease or disorder. In other embodiments, the kits are detection kits for screening animal products, such as blood, organs, tissues, or meat, for the presence of misfolded proteins associated with a disease or disorder. In yet other embodiments, the kits are detection kits for monitoring the progression of a disease or disorder associated with a misfolded protein.

[0080] In general, the kits of the invention comprise some or all of the components necessary to practice one or more embodiments of the invention. Thus, a kit of the invention can comprise at least one conformational probe, such as a capture peptide and/or detection-amplification peptide, that binds to a pre-defined misfolded protein. The probe(s) and other components can be provided in one or more suitable containers within the kit. The kit can also comprise some or all of the buffers, reagents, and supplies needed to incubate and/or separate probe(s) and sample(s) or probe-misfolded protein com-

plexes. The kit can comprise sufficient components to perform the method of the invention a single time or multiple times.

[0081] The containers of the kits can be any material suitable for containing one or more substances of the invention, such as a vial or ampule. The containers can be fabricated from materials such as glass, plastic, metal, paper, or a paper product. In some embodiments, the container is a glass or plastic ampule or vial that can be sealed, such as by a stopper, a stopper and crimp seal, or a plastic or metal cap such as a screw cap. In general, the container and seal are made of materials that can be sterilized by heat (dry or wet), radiation, or exposure to chemicals.

[0082] In some embodiments, the container comprises a sufficient amount of peptides to perform at least one embodiment of at least one method according to the invention. Thus, the kits can be, among other things, diagnostic kits, separation kits, test kits, or control kits. In some embodiments, the container is provided as a component of a larger kit, which includes suitable packaging and, optionally, instructions and other information relating to use of the peptides. Often, the kits will comprise some or all of the supplies and reagents to perform one or more control reactions to ensure the kits are performing properly and to provide baseline results against which test samples can be compared.

[0083] In certain configurations of the kits, the kit comprises multiple containers, each of which may contain peptides (conformational probes, i. e. capture peptides, and/or detection-amplification peptides) and other substances that are useful for performing one or more embodiment of a method of the invention. In embodiments where the kit comprises additional components or substances, they may be contained in the same or one or more different containers as the peptides and/or compositions. Where the kit comprises multiple containers or one container and other components, the containers and components are said to be in packaged combination within the kit. Where multiple containers are present, each container may contain enough peptide for practice of a single method of the invention, such as diagnosing misfolded proteins in a sample.

[0084] The kits of the invention can comprise substances that are useful for study of peptides and misfolded proteins. Such studies can comprise experiments to detect and/or study various peptide characteristics, functions, and effectiveness; to calibrate instruments; to separate misfolded proteins from a sample; to study interactions between peptide and microparticles (of various phases and activities); to calibrate peptide size; to calibrate separation techniques; to examine the interactions of various ligands and proteins; and to study surface-mediated reactions.

[0085] In some embodiments, the container is provided as a component of the kit, which includes suitable packaging and, optionally, instructions and/or other information relating to use of the contents of the kit. Typi-

cally, the kit is fabricated from a sturdy material, such as cardboard or plastic, and can contain the instructions or other information printed directly on it. One of skill in the art will immediately appreciate that numerous different configurations of container sizes and contents are envisioned by this invention, and thus not all permutations need be specifically recited herein.

EXAMPLES

[0086] The invention will now be described further in the following examples, which are illustrative of preferred embodiments of the invention, and should not be considered as limiting the invention in any way.

[0087] Example 1: Detection of Prion Protein in Biological Sample

[0088] A conformational propagation assay for prion protein in a murine brain sample was performed essentially as described in Published U.S. Patent Application 2005/0026265 A1, and as depicted in Figure 1. The assay was performed using the murine-specific pallindromic 33-mer probe depicted below (SEQ. ID. NO. 49), labeled at both ends with a pyrene label. Other probes for human/hamster and sheep/bovine prions are presented below as well, and can be used for detection of prions in those species.

H₂N-VVAGAAAAGAVHKLNTKPKLKHVAGAAA-
GAVV-COOH (murine sequence; SEQ. ID. NO. 53)
H₂N-VVAGAAAAGAMHKMNTKPKMA-
KHMAGAAAAGAVV-COOH (human/hamster se-
quence; SEQ. ID. NO. 54)
H₂N-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVV-COOH (sheep/bovine sequence;
SEQ. ID. NO. 55)

For improved labeling, the above sequences have been modified to contain an additional lysine (K) residue at the C-terminus (SEQ. ID. NOs. 56-58) to allow addition of a pyrene label.

H₂N-VVAGAAAAGAVHKLNTKPKLKHVAGAAA-
GAVVK-COOH (SEQ. ID. NO. 56)
H₂N-VVAGAAAAGAMHKMNTKPKM-
KHMAGAAAAGAVVK-COOH (SEQ. ID. NO. 57)
H₂N-VVAGAAAAGAVHKMNTKPKMKHVA-
GAAAAGAVVK-COOH (SEQ. ID. NO. 58).

[0089] Example 2: Demonstration of Kinetic Component of the Misfolded Protein Diagnostics (MPD) Assay Using Murine Brain Tissue

[0090] Murine brain tissue from Scrapie-infected and healthy animals was obtained and fractionated on a sucrose gradient. The MPD Assay of Example 1 was performed, using phosphotungstic acid as a precipitating reagent, followed by addition of the murine specific peptide probe. The mixture was allowed to react in Tris:TFE (50:50) mixture per the timecourse shown on the x-axis of

Figure 2. The results show suitable detection of prion protein in samples, which is above background levels for normal brain tissue.

[0091] Example 3: Fractionation of Prion-Containing Sample According to the Present Invention

[0092] Sheep serum was obtained and mixed with sheep-specific peptide (see sequences above), and the mixture was incubated for a sufficient amount of time to permit association of the probe with any prion protein in the serum. The mixture was applied directly to a Sepharose 4B column, and fractions collected. The fractions were analyzed for fluorescence by exciting at 350 nm and scanning from 350-600 nm on a luminescent plate reader. The luminescence of each fraction from healthy and infected sera is depicted in Figure 3. This data provides for visualization of elution of reactive fractions from the column. As can be seen, using the method of the present invention, not only can the infectious serum be distinguished from the healthy, it can occur in "real-time". Because the peptide was incubated with the sample prior to fractionation, the assay for misfolded protein is performed during the fractionation.

[0093] Example 4: MPD Assay of Non-fractionated Sheep Serum Samples

[0094] An MPD Assay was performed as follows. Normal and prion-infected sheep serum was obtained and applied directly to a Sepharose 4B column, and fractions collected. A solution of PBS was also run over a Sepharose 4B column for a negative control. In essence, this procedure was identical to that described in Figure 3, with the exception that probe was not added to the serum before fractionating over the Sepharose 4B column.

[0095] Separately for each sample (infected, uninfected, PBS), fractions determined from Example 3 to contain the highest signal-to-noise ratio were combined with sheep-specific probe and evaluated. The fraction showing the highest ratio of excimer to monomer from the infected sample was chosen for the kinetic experimental data shown here. The identical fraction number for the healthy and PBS control were also chosen. For the time-course (kinetic) experiment, sufficient time was provided for the probe to associate with any prion protein in the sample, using the typical 50:50 trifluoroethanol solvent conditions for the MPD Assay. The mixture was then assayed for fluorescence in a fluorescence scanning plate reader, and the data obtained is presented in Figure 4. The data show that, in a similar fashion to the data shown in Figure 2, the successful-Kinetics of the assay are apparent in fractionated sheep serum as well.

[0096] Example 5: Selective-Capture MPD with Human Plasma Samples

[0097] 200 ul samples of human plasma, either sCJD or pooled normal, were incubated with biotin-labeled peptide overnight. Dynal magnetic beads, coated with streptavidin, were added at the ratio of biotin peptide to beads of 25:100, 25:200, 50:100, or 0:100. A magnet was used to remove the enriched target material from the plasma samples. After washing and resuspending, a

double-labeled (pyrene) fluorophore peptide was added and after incubation, the emission scan captured. Figure 5 shows the successful signal separation between the sCJD plasma sample and pooled normal human plasma (NHP).

[0098] Example 6: Selective-Capture MPD Assay Dose Response

[0099] The same protocol as in Example 5 was followed, except that the sCJD 85-137 sample was diluted into normal human plasma 1:2, 1:4, and 1:8 (Figure 6). Dilution of neat human sCJD plasma into normal plasma resulted in a diminished fluorescence signal proportional and in a dose-response manner in the Selective Capture MPD Assay as expected. While the actual level of PrP^{TSE} present in the starting sCJD 85-137 sample is not known, as a clinical specimen, the expected maximum level would be 20-30 IU/ml. Using this approximation, with a testing volume of 200 ul, the neat sample would have contained 4-6 IU, and the two-fold serial dilutions of 1:2, 1:4 and 1:8 would have contained 2-3, 1-1.5, and 0.5-0.75 IU, respectively. These results reflect a LOD (level of detection) near 1 IU.

[0100] Example 7: Selective-Capture MPD Protocol with Sheep Serum Samples

[0101] The same protocol as in Example 5 was followed, except that the samples tested were two different Scrapie sheep serum samples and two normal healthy sheep serum samples (Figure 7). The Selective Capture MPD Protocol is successful for sheep serum samples. The signal-to-noise ratio is excellent between normal sheep serum and infected Scrapie (PrP^{Sc} or PrP^{TSE}) sheep serum.

[0102] Example 8: Effect of Sequential Washings of Captured sCJD Substrate from Magnetic Beads

[0103] Figure 8 shows direct evidence of binding of the PrP^{TSE} (sCJD 85-137) substrate to the biotin-labeled capture peptide, and effective interaction with the solid phase (magnetic beads). Repeated washings in PBS causes the PrP^{TSE} to dissociate. This experiment demonstrates that the interaction of the double-labeled fluorophore peptide is dependent upon what is associated with the "pull-down" material on the magnetic beads. The target (PrP^{TSE}) material is captured by the biotin-labeled peptide which itself associates with the streptavidin covering the surface of the magnetic beads. This material can be washed away with subsequent PBS washings. Figure 8 demonstrates that as the number of washings increases, the signal associated with the excimeric peak, *i.e.* 430-530 nm, of the fluorophore-labeled detection peptide is strongly diminished for the sCJD sample but not for the pooled normal human plasma sample. Specifically, Figures 8A and 8B show the excimer to monomer ratios of the two samples (Fig. 8A) and fluorescence scans showing peak emission (Fig. 8B) of the two samples without washing, while Figures 8C and 8D show data from the same assays after washing of the samples 3 times, while Figures 8E and 8F show data from the same assays after washing of the samples 5 times.

[0104] It will be apparent to those skilled in the art that various modifications and variations can be made in the practice of the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention. It is intended that the specification and examples be considered as exemplary only, with the invention being indicated by the following claims.

Claims

1. A method for detecting the presence or amount of prion protein or A Beta protein in a sample, said method comprising:

(a) combining

- (i) a sample containing or suspected of containing a prion protein or A Beta protein with
- (ii) a conformational biotin-labeled capture peptide to make a mixture,

wherein

- (ii.1) the conformational capture peptide has a size between 15 and 45 residues, an amino acid sequence that is at least 70% identical to any one of the amino acid sequences selected from SEQ. ID. NOs. 1, 4-35, and 44-58, and
- (ii.2) interacts with the pathogenic, misfolded form of the prion protein or A Beta protein and assumes a predominantly β -sheet conformation upon association with the protein,

(b) incubating the mixture for an amount of time sufficient to form a complex comprising an association of at least one molecule of prion protein or A Beta protein present in the sample and at least one molecule of conformational capture peptide,

(c) exposing the mixture to conditions that separate, at least partially, the complex, if present, from at least one other substance in the mixture, wherein the exposing step comprises binding the conformational capture probe, prion protein or A Beta protein, or complex thereof to a solid phase, and

(d) detecting the presence or absence of any association between the conformational capture peptide and any prion protein or A Beta protein.

2. The method of claim 1, further comprising, after the exposing step and prior to the detecting step, adding at least one detection-amplification double-labeled peptide to the complex, if present.

3. The method of any one of claims 1 or 2, wherein the incubating and exposing steps are carried out concurrently.

4. The method of any one of the preceding claims, wherein the protein is a prion protein.

5. The method of any one of claims 2 to 4, wherein at least one detection-amplification double-labeled peptide is selected from the group consisting of SEQ. ID. NOs. 2, 3, and 36-43.

6. The method of any one of the preceding claims, wherein at least one conformational capture peptide is selected from the group consisting of SEQ. ID. NOs. 1, 4-35, and 53-58.

7. The method of any one of claims 1 to 3, wherein the protein is an A Beta protein.

8. The method of claim 7, wherein at least one conformational capture peptide is selected from the group consisting of SEQ. ID. NOs. 44-52.

9. A kit comprising at least one conformational biotin-labeled capture peptide and at least one detection-amplification double-labeled peptide, wherein the conformational capture peptide has a size between 15 and 45 residues, an amino acid sequence that is at least 70% identical to any one of the amino acid sequences selected from SEQ. ID. NOs. 1, 4-35, and 44-58, and interacts with the pathogenic, misfolded form of a prion protein or an A Beta protein and assumes a predominantly β -sheet conformation upon association with the prion protein or A Beta protein, and further comprising a solid phase capable of binding the conformational capture probe, prion protein or A Beta protein, or complex thereof.

10. The kit of claim 9, wherein at least one conformational capture peptide is selected from the group consisting of SEQ. ID. NOs. 1, 4-35, and 44-58, and wherein at least one detection-amplification double-labeled peptide is selected from the group consisting of SEQ. ID. NOs. 2-3 and 36-43.

11. The method of any one of claims 2 to 8, wherein the amino acid sequence of the conformational capture peptide is substantially the same as the amino acid sequence of the detection-amplification double-labeled peptide.

12. The method of any one of claims 2 to 8, wherein the amino acid sequence of the conformational capture peptide is different from the amino acid sequence of the detection-amplification double-labeled peptide.

13. The method of any one of claims 2 to 12, wherein

- the detection-amplification double-labeled peptide interacts with the pathogenic, misfolded form of the prion protein or A Beta protein and assumes a predominantly β -sheet conformation upon association with the prion protein or A Beta protein.
14. The method of any one of claims 1 to 8 and 11 to 13, wherein the solid phase comprises one or more materials selected from the group consisting of cellulose, modified cellulose, lignocellulosic biomass, polystyrene, polypropylene, polyethylene, polylactide, polyacrylamide, silicon, rubber, polysaccharides, latex, polyvinyl fluoride, nylon, polyvinylchloride, polycarbonate, starch, dextran, chitin, sand, silica, pumice, agarose, glass, and metal.
15. The method of claim 14, wherein the solid phase is modified to increase the desired separation during the exposing step by a means selected from the group consisting of surface roughening, polarity induction, acid or base site generation, magnetic induction, thermal treatment, modification of hydrophobicity, and placement of a chemical or biologically active coating onto the solid surface.
16. The method of claim 14, wherein the solid phase comprises magnetic beads coated with streptavidin.
17. The method of any one of claims 1 to 8 or 11 to 16, wherein the at least one conformational capture peptide is labeled with a detectable label.
18. The method of any one of claims 1 to 8 or 11 to 17, wherein at least one conformational capture peptide is labeled with a detectable label at each end of the peptide.
19. The method of any one of claims 1 to 8 or 11 to 18, wherein a peptide comprises a moiety selected from the group consisting of radioactive isotopes, fluorescers, chemiluminescers, chromophores, fluorescent semiconductor nanocrystals, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, metal sols and ligands.
20. The method of claim 19, wherein the peptide comprises a moiety selected from the group consisting of pyrene butyrate, succinimidyl 1-pyrene, riboflavin, rosolic acid, 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid, acridine, 4-amino-N-[3-vinylsulfonyl] phenyl] naphthalimide-3,5 disulfonate, anthranilamide, coumarin, cyanosine, 4',6-diaminidino-2-phenylindole (DAPI), diethylenetriamine pentaacetate, 4,4'-diisothiocyanatodi-hydro-stilbene-2,2'-disulfonic acid, eosin, eosin isothiocyanate, erythrosin, erythrosin B, isothiocyanate, ethidium, fluorescein, 5-carboxyfluorescein (FAM), fluorescein, fluorescein isothiocyanate, fluorescarnine, nitrotyrosine, pararosaniline, Phenol Red, B-phycoerythrin, or o-phthalaldehyde.
21. The method of any one of claims 1 to 8 or 11 to 20, wherein the exposing step comprises using size-exclusion chromatography or filtration.
22. The method of any one claims 1 to 8 or 11 to 21, wherein the sample is a biological sample obtained from a living or once-living organism.
23. The method of any one of claims 1 to 8 or 11 to 22, wherein the biological sample is selected from the group consisting of human blood products, organs, whole blood, blood fractions, blood components, plasma, platelets, serum, cerebrospinal fluid, human tissues, brain tissue, nervous system tissue, muscle tissue, bone marrow, urine, and tears.
24. The method of any one of claims 1 to 8 or 11 to 23, further comprising monitoring the removal of pathogenic prion proteins or A Beta proteins at least at one point in time.
25. The method of any one of claims 1 to 8 or 11 to 24, wherein at least 25%, or at least 50%, or at least 75%, or at least 80%, or at least 90%, or at least 95%, or at least or at least 99.5% of the pathogenic prion proteins or A Beta proteins are removed from the sample.
26. The method of any one of claims 1 to 8 or 11 to 25, wherein the presence of an association between the conformational capture peptide and prion protein or A Beta protein is used to diagnose a disease associated with the protein.
27. The method of claim 1, further comprising after the exposing step and prior to the detecting step, adding at least one detection-amplification peptide labeled with a detectable label to the complex, if present.

Patentansprüche

1. Verfahren zum Nachweis des Vorhandenseins oder der Menge von Prion-Protein oder A-Beta-Protein in einer Probe, wobei das Verfahren umfasst:

(a) Kombinieren

- (i) einer Probe, enthaltend oder im Verdacht stehend, ein Prionprotein oder A-Beta-Protein zu enthalten, mit
- (ii) einem Biotin-markierten konformationellen Capture-Peptid, um eine Mischung herzustellen, wobei

(ii.1) das konformationelle Capture-Peptid eine Länge zwischen 15 und 45 Resten aufweist, eine Aminosäuresequenz, die zu mindestens 70 % mit einer beliebigen der Aminosäuresequenzen identisch ist, die ausgewählt sind aus SEQ. ID. NOs. 1, 4-35 und 44-58, und

(ii.2) mit der pathogenen, fehlgefalteten Form des Prion-Proteins oder A-Beta-Proteins interagiert und bei Assoziation mit dem Protein überwiegend eine β -Faltblatt-Struktur einnimmt,

(b) Inkubieren der Mischung für eine Zeitspanne, die ausreicht, um einen Komplex zu bilden, umfassend eine Assoziation von mindestens einem Molekül Prion-Protein oder A-Beta-Protein, das in der Probe vorhanden ist, und mindestens einem Molekül des konformationellen Capture-Peptids,

(c) Exponieren der Mischung unter Bedingungen, die den Komplex, falls vorhanden, von mindestens einer anderen Substanz in der Mischung zumindest teilweise trennen, wobei der Expositionsschritt die Bindung der konformationellen Capture-Sonde, des Prion-Proteins oder A-Beta-Proteins oder des Komplexes davon an eine feste Phase umfasst, und

(d) Nachweisen des Vorhandenseins oder der Abwesenheit jeglicher Assoziation zwischen dem konformationellen Capture-Peptid und einem Prion-Protein oder A-Beta-Protein.

2. Verfahren nach Anspruch 1, ferner umfassend nach dem Expositionsschritt und vor dem Nachweis-schritt, Hinzufügen mindestens eines doppelt markierten Nachweis-Amplifikationspeptids zu dem Komplex, falls vorhanden.
3. Verfahren nach einem der Ansprüche 1 oder 2, wobei die Inkubations- und Expositionsschritte gleichzeitig ausgeführt werden.
4. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Protein ein Prion-Protein ist.
5. Verfahren nach einem der Ansprüche 2 bis 4, wobei mindestens ein doppelt markiertes Nachweisverstärkungs-Peptid aus der Gruppe, bestehend aus SEQ. ID. NOs. 2, 3 und 36-43 ausgewählt ist.
6. Verfahren nach einem der vorhergehenden Ansprüche, wobei mindestens ein konformationelles Capture-Peptid aus der Gruppe bestehend aus SEQ. ID. NOs. 1, 4-35 und 53-58 ausgewählt ist.
7. Verfahren nach einem der Ansprüche 1 bis 3, wobei

das Protein ein A-Beta-Protein ist.

8. Verfahren nach Anspruch 7, wobei mindestens ein konformationelles Capture-Peptid aus der Gruppe bestehend aus SEQ. ID. NOs. 44-52 ausgewählt ist.
9. Kit, umfassend mindestens ein Biotin-markiertes konformationelles Capture-Peptid und mindestens ein doppelt markiertes Peptid zur Nachweisverstärkung, wobei das konformationelle Capture-Peptid eine Länge zwischen 15 und 45 Resten aufweist, eine Aminosäuresequenz, die zu mindestens 70 % mit einer beliebigen Aminosäuresequenz, ausgewählt aus SEQ. ID. NOs. 1, 4-35 und 44-58, identisch ist, und mit der pathogenen, fehlgefalteten Form eines Prion-Proteins oder eines A-Beta-Proteins interagiert und bei Assoziation mit dem Prion-Protein oder A-Beta-Protein überwiegend eine β -Faltblatt-Struktur einnimmt, und ferner umfassend eine feste Phase, die in der Lage ist, die konformationelle Capture-Sonde, das Prion-Protein oder A-Beta-Protein oder einen Komplex derselben zu binden.
10. Kit nach Anspruch 9, wobei mindestens ein konformationelles Capture-Peptid aus der Gruppe bestehend aus SEQ. ID. NOs. 1, 4-35 und 44-58 ausgewählt ist und wobei mindestens ein doppelt markiertes Nachweisverstärkungs-Peptids aus der Gruppe, bestehend aus SEQ. ID. NOs. 2-3 und 36-43 ausgewählt ist.
11. Verfahren nach einem der Ansprüche 2 bis 8, wobei die Aminosäuresequenz des konformationellen Capture-Peptids im Wesentlichen dieselbe ist wie die Aminosäuresequenz des doppelt markierten Nachweisverstärkungs-Peptids.
12. Verfahren nach einem der Ansprüche 2 bis 8, wobei die Aminosäuresequenz des konformationellen Capture-Peptids sich von der Aminosäuresequenz des doppelt markierten Peptids zur Nachweisverstärkung unterscheidet.
13. Verfahren nach einem der Ansprüche 2 bis 12, wobei das doppelt markierte Peptid zur Nachweisverstärkung mit der pathogenen, fehlgefalteten Form des Prion-Proteins oder A-Beta-Proteins interagiert und bei Assoziation mit dem Prion-Protein oder dem A-Beta-Protein überwiegend eine β -Faltblatt-Struktur einnimmt,
14. Verfahren nach einem der Ansprüche 1 bis 8 und 11 bis 13, wobei die feste Phase ein Material oder mehrere Materialien umfasst, ausgewählt aus der Gruppe bestehend aus Zellulose, modifizierter Zellulose, lignozellulosehaltiger Biomasse, Polystyrol, Polypropylen, Polyethylen, Polylactid, Polyacrylamid, Silicium, Kautschuk, Polysaccharide, Latex, Polyvinyl-

- fluorid, Nylon, Polyvinylchlorid, Polycarbonat, Stärke, Dextran, Chitin, Sand, Siliciumdioxid, Bimsstein, Agarose, Glas und Metall.
15. Verfahren nach Anspruch 14, wobei die feste Phase modifiziert ist, um die gewünschte Trennung während des Expositionsschrittes durch ein Mittel zu verstärken, das ausgewählt ist aus der Gruppe bestehend aus Aufrauen der Oberfläche, Polaritätsinduktion, Erzeugung einer Säure- oder Basestelle, magnetischer Induktion, Wärmebehandlung, Modifikation der Hydrophobie und Aufbringen einer chemisch oder biologisch aktiven Beschichtung auf die feste Oberfläche.
16. Verfahren nach Anspruch 14, wobei die feste Phase mit Streptavidin beschichtete Magnetbeads umfasst.
17. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 16, wobei das mindestens eine konformationelle Capture-Peptid mit einem nachweisbaren Marker markiert ist.
18. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 17, wobei mindestens ein konformationelles Capture-Peptid mit einem nachweisbaren Marker an jedem Ende des Peptids markiert ist.
19. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 18, wobei ein Peptid eine funktionelle Gruppe umfasst, ausgewählt aus der Gruppe bestehend aus radioaktiven Isotopen, Fluoreszenzmitteln, Chemilumineszenzmitteln, Chromophoren, fluoreszierenden Halbleiter-Nanokristallen, Enzymen, Enzymsubstraten, Enzymcofaktoren, Enzyminhibitoren, Färbemitteln, Metallionen, Metallsolen und Liganden.
20. Verfahren nach Anspruch 19, wobei das Peptid eine funktionelle Gruppe umfasst, ausgewählt aus der Gruppe bestehend aus Pyrenbutyrat, Succinimidyl-1-pyren, Riboflavin, Rosolsäure, 4-Acetamido-4'-isothiocyanatostilben-2,2'-disulfonsäure, Acridin, 4-Amino-N-[3-(vinylsulfonyl)phenyl]naphthalimid-3,5-disulfonat, Anthranilamid, Cumarin, Cyanosin, 4',6-Diaminidino-2-phenylindol (DAPI), Diethylenetriaminpentaacetat, 4,4'-Diisothiocyanatodihydrostilben-2,2'-disulfonsäure, Eosin, Eosinisothiocyanat, Erythrosin, Erythrosin B, Isothiocyanat, Ethidium, Fluorescein, 5-Carboxyfluorescein (FAM), Fluorescein, Fluoresceinisothiocyanate, Fluorescamin, Nitrotyrosin, Pararosanilin, Phenolrot, B-Phycoerythrin oder o-Phthaldialdehyd.
21. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 20, wobei der Expositionsschritt die Verwendung von Größenausschlusschromatographie oder Filtration umfasst.
22. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 21, wobei die Probe eine biologische Probe ist, die von einem lebenden oder vormals lebenden Organismus gewonnen wurde.
23. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 22, wobei die biologische Probe aus der Gruppe ausgewählt ist, bestehend aus humanen Blutprodukten, Organen, Vollblut, Blutfraktionen, Blutbestandteilen, Plasma, Blutplättchen, Serum, Liquor, humanen Geweben, Hirngewebe, Gewebe des Nervensystems, Muskelgewebe, Knochenmark, Urin und Tränenflüssigkeit.
24. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 23, ferner umfassend die Überwachung des Entfernens von pathogenen Prion-Proteinen oder A-Beta-Proteinen zu mindestens einem Zeitpunkt.
25. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 24, wobei mindestens 25% oder mindestens 50% oder mindestens 75% oder mindestens 80% oder mindestens 90% oder mindestens 95% oder mindestens 99% oder mindestens 99.5% der pathogenen Prion-Proteine oder der A-Beta-Proteine aus der Probe entfernt sind.
26. Verfahren nach einem der Ansprüche 1 bis 8 oder 11 bis 25, wobei das Vorhandensein einer Assoziation zwischen dem konformationellen Capture-Peptid und dem Prion-Protein oder A-Beta-Protein dazu dient, eine Erkrankung, die mit dem Protein assoziiert ist zu diagnostizieren.
27. Verfahren nach Anspruch 1, ferner umfassend nach dem Expositionsschritt und vor dem Nachweisschritt das Hinzufügen mindestens eines Peptid zur Nachweisverstärkung, das mit einem nachweisbaren Marker markiert ist, zu dem Komplex, falls vorhanden.
- Revendications**
1. Procédé de détection de la présence ou de la quantité de protéines de prion ou de protéine A bêta dans un échantillon, ledit procédé comprenant :
- (a) la combinaison
- (i) d'un échantillon contenant ou suspecté de contenir une protéine de prion ou une protéine A bêta avec
- (ii) un peptide de capture conformationnel marqué à la biotine afin de créer un mélange, étant donné que

- (ii.1) le peptide de capture conformationnel a une taille située entre 15 et 45 résidus, une séquence d'acides aminés qui est au moins à 70% identique à l'une quelconque des séquences d'acides aminés sélectionnées parmi les SEQ. ID. NOs. 1, 4-35, et 44-58, et (ii.2) interagit avec la forme pathogène mal repliée de la protéine de prion ou la protéine A bêta et suppose une conformation en feuillets β prédominante en cas d'association avec la protéine,
- (b) l'incubation du mélange pendant une durée de temps suffisante pour former un complexe comprenant une association d'au moins une molécule de protéine de prion ou de protéine A bêta présente dans l'échantillon et au moins une molécule de peptide de capture conformationnel,
- (c) l'exposition du mélange à des conditions qui séparent, au moins partiellement, le complexe, s'il est présent, de l'au moins une autre substance dans le mélange, étant donné que l'étape d'exposition comprend la liaison de la sonde de capture conformationnelle, la protéine de prion ou protéine A bêta, ou le complexe de ces derniers en une phase solide, et
- (d) la détection de la présence ou de l'absence de n'importe quelle association entre le peptide de capture conformationnel et toute protéine de prion ou protéine A bêta.
2. Procédé selon la revendication 1, comprenant en outre, après l'étape d'exposition et avant l'étape de détection, l'addition d'au moins un peptide à double marqueur pour amplification de la détection au complexe, s'il existe.
 3. Procédé selon l'une quelconque des revendications 1 à 2, dans lequel les étapes d'incubation et d'exposition sont réalisées en même temps.
 4. Procédé selon l'une quelconque des revendications précédentes, dans lequel la protéine est une protéine de prion.
 5. Procédé selon l'une quelconque des revendications 2 à 4, dans lequel au moins un peptide à double marqueur pour amplification de la détection est sélectionné dans le groupe constitué des SEQ. ID. NOs. 2, 3, et 36-43.
 6. Procédé selon l'une quelconque des revendications précédentes, dans lequel au moins un peptide de capture conformationnel est sélectionné dans le groupe constitué des SEQ. ID. NOs. 1, 4-35, et 53-58.
 7. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel la protéine est une protéine A bêta.
 8. Procédé selon la revendication 7, dans lequel au moins un peptide de capture conformationnel est sélectionné dans le groupe constitué des SEQ. ID. NOs. 44-52.
 9. Kit comprenant au moins un peptide de capture conformationnel marqué à la biotine et au moins un peptide à double marqueur pour amplification de la détection, étant donné que le peptide de capture conformationnel a une taille située entre 15 et 45 résidus, une séquence d'acides aminés qui est au moins à 70% identique à l'une quelconque des séquences d'acides aminés sélectionnées parmi les SEQ. ID. NOs. 1, 4-35, et 44-58, et interagit avec la forme pathogène mal repliée de la protéine de prion ou la protéine A bêta et suppose une conformation en feuillets β prédominante en cas d'association avec la protéine, et comprend en outre une phase solide capable de lier la sonde de capture conformationnelle, la protéine de prion ou protéine A bêta, ou le complexe de ces derniers.
 10. Kit selon la revendication 9, dans lequel au moins un peptide de capture conformationnel est sélectionné dans le groupe constitué des SEQ. ID. NOs. 1, 4-35, et 44-58, et dans lequel au moins un peptide à double marqueur pour amplification de la détection est sélectionné dans le groupe constitué des SEQ. ID. NOs. 2-3 et 36-43.
 11. Procédé selon l'une quelconque des revendications 2 à 8, dans lequel la séquence d'acides aminés du peptide de capture conformationnel est essentiellement la même que la séquence d'acides aminés du peptide à double marqueur pour amplification de la détection.
 12. Procédé selon l'une quelconque des revendications 2 à 8, dans lequel la séquence d'acides aminés du peptide de capture conformationnel est différent de la séquence d'acides aminés du peptide à double marqueur pour amplification de la détection.
 13. Procédé selon l'une quelconque des revendications 2 à 12, dans lequel le peptide à double marqueur pour amplification de la détection interagit avec la forme pathogène mal repliée de la protéine de prion ou la protéine A bêta et suppose une conformation en feuillets β prédominante en cas d'association avec la protéine de prion ou la protéine A bêta.
 14. Procédé selon l'une quelconque des revendications 1 à 8 et 11 à 13, dans lequel la phase solide comprend un ou plusieurs matériaux sélectionnés dans le groupe constitué de cellulose, cellulose modifiée,

- biomasse lignocellulosique, polystyrène, polypropylène, polyéthylène, polylactide, polyacrylamide, silicium, caoutchouc, polysaccharides, latex, fluorure de polyvinyle, nylon, chlorure de polyvinyle, polycarbonate, amidon, dextrane, chitine, sable, silice, pumice, agarose, verre, et métal.
- 5
15. Procédé selon la revendication 14, dans lequel la phase solide est modifiée de manière à amplifier la séparation souhaitée pendant l'étape d'exposition à l'aide d'un moyen sélectionné dans le groupe constitué de grattage de surface, induction de polarité, génération de site d'acide ou de base, induction magnétique, traitement thermique, modification d'hydrophobicité, et placement d'un revêtement chimiquement ou biologiquement actif sur la surface solide.
- 10
16. Procédé selon la revendication 14, dans lequel la phase solide comprend des perles magnétiques revêtues de streptavidine.
- 15
17. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 16, dans lequel le au moins un peptide de capture conformationnel est identifié par un marqueur détectable.
- 20
18. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 17, dans lequel au moins un peptide de capture conformationnel est identifié par un marqueur détectable à chaque extrémité du peptide.
- 25
19. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 18, dans lequel un peptide comprend une fraction sélectionnée dans le groupe constitué d'isotopes radioactifs, agents fluorescents, agents chimioluminescents, chromophores, nanocristaux semi-conducteurs fluorescents, enzymes, substrats d'enzymes, cofacteurs d'enzymes, inhibiteurs d'enzymes, colorants, ions métalliques, sels métalliques et ligands.
- 30
20. Procédé selon la revendication 19, dans lequel le peptide comprend une fraction sélectionnée dans le groupe constitué de butyrate de pyrène, succinimidyl 1-pyrène, riboflavine, acide rosolique, 4-acétamido-4'-isothiocyanatostilbène-2,2'-acide disulfonique, acridine, 4-amino-N-[3-vinylsulfonyl] phényl] naphthalimide-3,5 disulfonate, anthranilamide, coumarine, cyanosine, 4',6-diaminidino-2-phénylindole (DAPI), diéthylènetriamine pentaacétate, 4,4'-diisothiocyanatodi-hydro-stilbène-2,2'-acide disulfonique, éosine, isothiocyanate d'éosine, érythrosine, érythrosine B, isothiocyanate, éthidium, fluorescéine, 5-carboxyfluorescéine (FAM), fluorescéine, isothiocyanate de fluorescéine, fluorescarnine, nitrotyrosine, pararosanine, phénol Red, B-phycoérythrine, ou o-phthaldialdéhyde.
- 35
21. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 20, dans lequel l'étape d'exposition comprend l'utilisation de chromatographie d'exclusion de taille ou la filtration.
- 40
22. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 21, dans lequel l'échantillon est un échantillon biologique obtenu d'un organisme vivant ou qui a vécu.
- 45
23. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 22, dans lequel l'échantillon biologique est sélectionné dans le groupe constitué de produits du sang humain, organes, sang total, fractions de sang, composants du sang, plasma, plaquettes sanguines, sérum, liquide cérébro-spinal, tissus humains, tissu cérébral, tissu du système nerveux, tissu musculaire, moëlle osseuse, urine, et larmes.
- 50
24. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 23, comprenant le monitoring de l'extraction de protéines de prion ou de protéines A bêta à au moins un moment.
- 55
25. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 24, dans lequel au moins 25%, ou au moins 50%, ou au moins 75%, ou au moins 80%, ou au moins 90%, ou au moins 95%, ou au moins 99%, ou au moins 99.5% des protéines de prion ou protéines A bêta pathogènes sont enlevées de l'échantillon.
26. Procédé selon l'une quelconque des revendications 1 à 8 ou 11 à 25, dans lequel la présence d'une association entre le peptide de capture conformationnel et la protéine de prion ou protéine A bêta est utilisée pour diagnostiquer une maladie associée à la protéine.
27. Procédé selon la revendication 1, comprenant en outre, après l'étape d'exposition et avant l'étape de détection, l'addition d'au moins un peptide d'amplification de la détection marqué avec un marqueur détectable au complexe, s'il existe.

Figure 1




Figure 2
Kinetics of the MPD Assay




Figure 3




Figure 4
Kinetics of MPD Assay:
Enriched Sheep Plasma




Figure 5




Figure 6




Figure 7




Figure 8A




Figure 8B




Figure 8C




Figure 8D




Figure 8E





Figure 8F



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 65273305 P [0001]
- US 20050026165 A1 [0011] [0047]
- WO 02097444 A2 [0011]
- WO 2006031644 A [0012]
- US 20050026265 A1 [0088]

Non-patent literature cited in the description

- **Grosset et al.** *Peptides*, 2005, vol. 26, 2193-2200 [0012]
- **Tcherkasskaya et al.** *Journal of Biomolecular Structure & Dynamics*, 2003, vol. 21 (3), 353-365 [0012]
- *Physical Biochemistry: Applications to Biochemistry and Molecular Biology.* W.H. Freeman & Co, 1982 [0037]
- *Fluorescence Spectroscopy.* Methods in Enzymology. Academic Press, Inc, 1997, vol. 278 [0042]
- *Amyloid, Prions and Other Protein Aggregates.* Methods in Enzymology. Academic Press, Inc, 1999, vol. 309 [0042]
- *Handbook of Experimental Immunology.* Blackwell Scientific Publications, 1986, vol. I-IV [0042]
- *Handbook of Surface and Colloidal Chemistry.* CRC Press, 1997 [0042]

专利名称(译)	检测错误折叠的蛋白质和朊病毒的方法		
公开(公告)号	EP1853915B1	公开(公告)日	2011-10-12
申请号	EP2006720716	申请日	2006-02-14
申请(专利权)人(译)	ADLYFE INC.		
当前申请(专利权)人(译)	ADLYFE INC.		
[标]发明人	ORSER CINDY S PAN TAO SETHI JASMEET		
发明人	ORSER, CINDY, S. PAN, TAO SETHI, JASMEET		
IPC分类号	G01N33/53 G01N33/566 C07K17/00 B01L3/00		
CPC分类号	G01N33/54333 G01N2800/2828		
优先权	60/652733 2005-02-15 US		
其他公开文献	EP1853915A2 EP1853915A4		
外部链接	Espacenet		

摘要(译)

本发明提供了用于检测样品中构象改变的蛋白质（例如朊病毒或与疾病状态相关的其他蛋白质）的方法和试剂盒。该方法包括从干扰这种复合物检测的物质中选择性捕获和分离肽和构象改变的蛋白质的复合物，并优选扩增检测信号和第二种双标记肽的添加。

